The devil is in the details
|
|
- Lee Mitchell
- 6 years ago
- Views:
Transcription
1
2 The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from unnecessary interventions. 1,2
3 In cervical cancer screening Protect women from cervical cancer and from overtreatment The goals of cervical cancer screening have remained elusive Identifying as many women as possible at risk of precancer Balancing high sensitivity and negative predictive value with high specificity to protect women from unnecessary interventions and lower the burden on the healthcare system Cytology has a changing role Cytology screening, including triage of abnormal cytology results, has been useful in significantly reducing the incidence and mortality rate of cervical cancer 3 Cytology has relatively low sensitivity, resulting in missed disease in women 1 Variable sample quality and subjective interpretation of cell morphology means Pap tests alone may not catch women at high risk or who have pre-cervical cancer 1 Cytology does not reliably detect cellular changes caused by adenocarcinoma 4 Normal cytology does not always mean cancer-free Up to one-third of cervical cancers occur in screened women with normal Pap cytology 5.6 New strategies are needed to deliver improved patient care while avoiding unnecessary treatment The discovery of HPV as the cause of cervical cancer revolutionized cervical cancer prevention strategies 2,3,7 Evidence supports moving to testing for primary screening of cervical cancer 2 - In primary screening, testing was proven more sensitive than cytology for detecting CIN2+ and CIN3+ 8 Pooled testing has high sensitivity but lacks specificity, accurately identifying women harboring disease, but resulting in false identification of healthy women, leading to unnecessary colposcopy 9 Evidence supports that there is an opportunity to identify those at highest risk, since 70% of cervical cancers are caused by HPV genotypes 16 and 18 3 The case for using the cobas for primary screening In the ATHENA study, the cobas found 92% of cases of CIN3 in the overall population compared to 53% found by cytology 1 cobas detected more CIN3 cases in overall population than liquid-based cytology 1 cobas 252 In the ATHENA study, 274 cases of CIN3 were found in a screening population of 47,208 women; the cobas found 252 (92%) of these cases. found 146 (53%) of these cases Emerging strategies 32 % 24 % Kaiser Permanente and 2 other healthcare plans 5 N = 833 Swedish healthcare system 6 N = 1230 The cobas offers an opportunity to strive for both goals of screening it provides pooled results on the known 12 high-risk genotypes and individual results on the highest-risk genotypes HPV 16 and 18, identifying women with the highest likelihood of harboring high-grade disease, while following a triage strategy that protects women from unnecessary intervention 1 Percentage of invasive cervical cancer that occurred in women with normal cytology 5,6 High-risk HPV genotypes Highest-risk HPV genotypes
4 Pooled testing provides only part of the answer Preventing more cancer over time than cytology 2,10 Pooled testing provides increased sensitivity for disease A systematic evidence review of randomized studies shows pooled test sensitivity was 86% 97% vs 46% 50% for cytology for a CIN3, and the range for CIN2 was 63% 98% for compared to 38% 65% for cytology 8 The clinical dilemma: The HPV-positive woman CONFIDENCE P HPV-negative QUESTION? HPV-positive Sensitivity for CIN2 (%) Bigras (N=13,842) Cardenas (N=1,850) Sensitivity of cytology vs for CIN2 Coste (N=3,080) Kulasingam (N=774) Mayrand (N=9,977) Petry (N=7,908) Average increase 36% test Cytology Absolute test performance of primary screening with HPV testing alone compared to cytology alone in developed countries in women aged 30 years or older 8 99% negative predictive value 1 Long-term protective benefit of DNA is well proven 1 High risk of false-positives due to lack of specificity 3 False-positives have an unnecessary adverse psychosocial impact on women 12 Pooled testing Pooled testing allows detection and treatment of precancers missed by cytology, thereby preventing more cancer than cytology alone 10 In a randomized controlled trial of 94,370 women, no cancers were found in the second round of screening among HPV-positive women referred to colposcopy in the first round, indicating that all precancers were identified in the initial round 10 A woman negative for HPV can be managed differently than a woman positive for high-risk genotypes 11 Following each -positive test result with colposcopy places large burden on the healthcare system Screening Round 1 (time 0) Round 1 Cancer Round 1 CIN The screening interval can be safely extended for HPV-negative women 11 Dilemma: Inability to discern who would benefit from immediate colposcopy without further triage 9 Screening Round 2 (+4 years) Round 2 Cancer Round 2 CIN3 0 HPV 0 cases of cancer detected Total Total Cancer Total CIN HPV Cytology Triage strategies are needed to determine who would benefit most from colposcopy now vs those who could be managed less aggressively. This would maximize the benefits of cervical cancer screening while decreasing the potential harm. 9 No. of cases HPV-based screening reduces the incidence of cervical cancer within 4 5 years, compared to cytology-based screens. 2,10
5 HPV 16 and HPV 18 bring clarity Adding greater specificity to pooled Focus on women at the highest risk HPV 16 and HPV 18 are responsible for approximately two-thirds of cervical cancer cases 3 Women HPV 16-positive and HPV 18-positive are at increased risk of CIN3, even if they have normal baseline and repeat cytologies 13 In a 10-year study of women with normal cytology, women HPV 16-positive or HPV 18-positive were more likely to have CIN3 over a 10-year period than women who were positive for other pooled HPV genotypes 14 For women who were HPV 16-positive at baseline, the incidence rose sharply during the first year of the study 14 For HPV 18-positive women, the incidence of CIN3 increased from around 2 years after baseline year cumulative incidence rate of CIN3 by status 14 HPV 16 and HPV 18 cause 70% of cervical cancers and are the two most prevalent oncogenic HPV genotypes in both squamous cell carcinoma and adenocarcinoma 4 Cumulative Incidence Rate, % (Confidence Interval) Follow-up Time (months) HPV % (11.5, 22.9) HPV % (3.6, 23.7) Other pooled 3.0% (1.9, 4.2) HPV 0.8% (0.6, 1.1) HPV 16 causes 55% 60% of cervical cancer 3 HPV 18 causes a significant proportion of adenocarcinomas, which are hard to detect by cytology 4 The pooled HPV genotypes were as follows: HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Adapted from Khan MJ, et al. J Natl Cancer Inst. 2005;97: HPV 16 and HPV 18 genotyping add specificity to further define risk 1 Adding HPV 16/18 genotyping to a pooled with cytology triage strategy maintains sensitivity and adds greater specificity, and therefore, greater positive predictive value vs the current standard of care. 1,15 HPV 16 and HPV 18 Conforms to US guidelines, which recognize the benefits of identifying HPV 16 or HPV 16/18. 3 The cobas KNOW THE RISK
6 The cobas 3 tests in 1 for confident risk stratification ATHENA: Powered to change the standard of testing 1 ATHENA is a multicenter, prospective trial of more than 47,000 women 21 years of age undergoing routine cervical cancer screening. The cobas is the only clinically validated, CE-marked and FDA-approved* test that simultaneously provides pooled results on known high-risk genotypes and individual results on the 2 highestrisk genotypes, HPV 16 and HPV 18, giving 3 results in just 1 test. Most HPV tests 14 pooled cobas pooled STUDY VISIT 1: STUDY VISIT 2: Cytology and HPV testing were performed on all women. All women with ASC-US cytology or -positive test results and a random subset of women 25 years of age who had normal cytology and were negative underwent colposcopy and biopsy. 14 pooled: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 ATHENA The most comprehensively designed, evidence-based study ever conducted to evaluate HPV screening strategies 1,16 The ATHENA trial (N=47,208) is a landmark study and is the largest US registration study for cervical cancer screening, and the only study to assess the value of simultaneous HPV 16 and 18 genotyping in risk assessment of women 16 Supports effective triage at primary screening by providing high sensitivity with testing and high specificity by isolating the highest cervical cancer risk HPV genotypes to identify patients who need immediate intervention 1 The ATHENA trial evaluated the performance of the cobas in multiple clinical situations representing 3 scenarios for its intended use, including 16 : 1. As a triage test for ASC-US cytology in cytology-based screening (ASC-US triage) 2. As a screening test alongside cytology (co-testing) 3. As a stand-alone screening test (primary screening)* 3-YEAR LONGITUDINAL FOLLOW-UP: Women without a histological diagnosis of CIN2 had annual follow-up visits for the next 3 years, at which those with abnormal cytology undergo colposcopy and biopsy; those with a histologic diagnosis of CIN2 exited the study. Exit colposcopy was offered to all women. Women with a histological diagnosis of CIN2 met the endpoint and exited the study. Because the devil is in the details, order the evidence-based cobas *The cobas is not approved for primary screening in the US. Addressing THE Need for Advanced HPV Diagnostics The cobas KNOW THE RISK cobas
7 The cobas Integral to cervical cancer prevention The optimal primary screening strategy focuses medical attention on women with genotypes HPV 16 and HPV 18, and triages other high-risk genotypes. 2,9 The potential to set the new standard of care, providing significantly enhanced patient risk stratification 9,18 Primary screening strategies for the detection of CIN3 endpoint 9 Cytology with reflex HPV Current standard of care Had low sensitivity for detection of CIN3 9 Less efficient strategy, as it requires frequent screening (at least every 2 3 years) 9, HPV with genotyping and reflex cytology 72% CIN3 cases 7.2 colposcopies per CIN3 case HPV with genotyping and reflex cytology HPV with reflex cytology Almost 1.3 times more cases than the current standard of care 9 care, as only 7.2 colposcopies were necessary to detect a single case of CIN3 vs 7.7 9,17 Identified a similar amount of disease as strategy that used cytology as primary screen 9 care, as 6.1 colposcopies were needed to detect a single case of CIN3 vs the 7.7 required by cytology 9,17 % of CIN3 cases at baseline detected HPV screening alone 90% CIN3 cases 13.8 colposcopies per CIN3 case HPV with reflex cytology 52% CIN3 cases 6.1 colposcopies per CIN3 case Cytology with reflex HPV 56% CIN3 cases 7.7 colposcopies per CIN3 case # of colposcopies to detect a single case of CIN3 Most sensitive screening strategy finding significantly more disease than cytology alone 9 HPV screening alone Highest false-positive rate for CIN3 9 Inefficient strategy, as it required 13.8 colposcopies to find a single case of CIN3 9,17
8 % of CIN3 cases at baseline detected The cobas Integral to cervical cancer prevention The optimal primary screening strategy focuses medical attention on women with genotypes HPV 16 and HPV 18, and triages other high-risk genotypes. 2,9 The potential to set the new standard of care, providing significantly enhanced patient risk stratification 9,18 Cytology with reflex HPV Current standard of care Had low sensitivity for detection of CIN3 9 Less efficient strategy, as it requires frequent screening (at least every 2 3 years) 9,17 Primary screening strategies for the detection of CIN3 endpoint NILM ASC-US LSIL/HSIL HPV test Negative Positive HPV with genotyping and reflex cytology 72% CIN3 cases 7.2 colposcopies per CIN3 case HPV with genotyping and reflex cytology Almost 1.3 times more cases than the current standard of care 9 care, as only 7.2 colposcopies were necessary to detect a single case of CIN3 vs 7.7 9,17 cobas HPV- HPV 16/18+* 60 HPV screening alone 90% CIN3 cases 13.8 colposcopies per CIN3 case NILM ASC-US Follow-up in 12 months HPV with reflex cytology Identified a similar amount of disease as strategy that used cytology as primary screen 9 care, as 6.1 colposcopies were needed to detect a single case of CIN3 vs the 7.7 required by cytology 9,17 test HPV- NILM ASC-US HPV with reflex cytology 52% CIN3 cases 6.1 colposcopies per CIN3 case Cytology with reflex HPV 56% CIN3 cases 7.7 colposcopies per CIN3 case Follow-up in 12 months HPV screening alone Most sensitive screening strategy finding significantly more disease than cytology alone 9 Highest false-positive rate for CIN3 9 Inefficient strategy, as it required 13.8 colposcopies to find a single case of CIN3 9,17 test HPV- # of colposcopies to detect a single case of CIN3 *HPV 16-positive and/or 18-positive
9 The cobas Integral to cervical cancer prevention The optimal primary screening strategy focuses medical attention on women with genotypes HPV 16 and HPV 18, and triages other high-risk genotypes. 2,9 Almost 1.3 times more cases than the current standard of care Balances detected cases and intervention Screening tests % of CIN3 cases detected at baseline Colposcopies Colposcopies to detect 1 case of CIN3 Cytology with reflex HPV Current standard of care Had low sensitivity for detection of CIN3 9 Less efficient strategy, as it requires frequent NILM Negative ASC-US HPV test 35,546 56% screening (at least every 2 3 years) 9,17 Positive LSIL/HSIL HPV with genotyping and reflex cytology Almost 1.3 times more cases than the current standard of care 9 cobas ,423 72% 982 ASC-US to detect a single case of CIN3 vs 7.7 9, HPV 16/18+* care, as only 7.2 colposcopies were necessary HPV- HPV- NILM Follow-up in 12 months 7.2 HPV with reflex cytology Identified a similar amount of disease as strategy that used cytology as primary screen 9 care, as 6.1 colposcopies were needed to detect a single case of CIN3 vs the 7.7 HPV required by cytology 9, test NILM ASC-US Follow-up in 12 months 37,126 52% HPV screening alone Most sensitive screening strategy finding significantly more disease than cytology alone test ,254 90% 2, colposcopies to find a single case of CIN3 9, Highest false-positive rate for CIN3 9 Inefficient strategy, as it required 13.8 *HPV 16-positive and/or 18-positive Total CIN3 cases = 189 Total number of women screened = 34,254
10 The cobas An evidence-based approach to primary screening Help protect women from cervical cancer and from overtreatment The cobas, a pooled high-risk HPV test with simultaneous HPV 16 and HPV 18 genotyping, enables clinicians to use pooled HPV testing with or without individual HPV 16/18 genotyping to achieve significant advantages over the current standard of care 9 Allows early and efficient stratification of the few women who require aggressive intervention and those who are at very low risk 9 Permits confident extension of screening intervals 11 Identifies women who can return to routine screening 11 Conforms to US guidelines, which recognize the benefits of identifying HPV 16 or HPV 16/18 1 Use of simultaneous HPV 16/18 genotyping finds more cases of disease while reducing the burden on the healthcare system, compared to cytology-based screening 9 The devil is in the details, so implement primary screening with the cobas REFERENCES: 1. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study [published online August 23, 2011]. Lancet Oncol. doi: /s (11) Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13: Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4): Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol. 2007;197(6): Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97(9): Andrae B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100(9): Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31: Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(10): Cox JT, Castle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Ob Gyn. 2012:In Press. 10. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3): Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7): Gray NM, Sharp L, Cotton SC, et al. Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors. British J Cancer. 2006:94(9): Berkhof J, Bulkmans NWJ, Bleeker MCG, et al. Human papillomavirus type specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev. 2006;15(7): Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14): Stoler MH, Wright TC Jr, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;136: cobas [package insert, US]. Branchburg, NJ: Roche Molecular Systems, Inc.; Data on file, Roche Molecular Diagnostics, Inc. 18. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derrion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206(1):46.e1-46.e11. The cobas KNOW THE RISK For more information, go to COBAS is a trademark of Roche Roche Molecular Systems, Inc. Roche Molecular Diagnostics, Inc., 4300 Hacienda Drive, Pleasanton, CA USA
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationCervical cancer prevention: Advances in primary screening and triage system
Cervical cancer prevention: Advances in primary screening and triage system Dr Farid Hadi Regional Medical and Scientific Affairs Roche Diagnostics Asia-Pacific, Singapore Cervical cancer is highly preventable
More informationThe data from the ATHENA study and others bring this expectation and the appropriateness of the guidelines for women aged into question.
New data support HPV testing beginning at age 25 By Hope Cottrill, M.D. Recent findings from the ATHENA (Addressing the Need for Advanced HPV Diagnostics) study of cervical cancer screening revealed surprising
More informationThe clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way
The clearest path to the most meaningful results The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way The cobas HPV Test KNOW THE RISK Help guide clinical decision
More informationEvidence-based treatment of a positive HPV DNA test. Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR
Evidence-based treatment of a positive HPV DNA test Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR HPV DNA testing Indications 1. Triage after cytology with ASCUS/LSIL
More informationBiomarkers and HPV testing: The future of cervical screening
THE FUTURE OF CERVICAL SCREENING Earn 3 CPD Points online Biomarkers and HPV testing: The future of cervical screening Professor John O Leary Associate Professor and Director of Pathology Coombe Women
More informationHUMAN PAPILLOMAVIRUS TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HUMAN PAPILLOMAVIRUS TESTING Policy Number: PDS - 016 Effective Date: October 1, 2018
More informationHPV Primary Screening in the United States
IFCPC 15th World Congress May 2014, London, UK. HPV Primary Screening in the United States E.J. Mayeaux, Jr., M.D. Professor and Chairman Department of Family and Preventive Medicine Professor of Obstetrics
More informationGoals. In the News. Primary HPV Screening 3/9/2015. Your PAP and HPV Update Primary HPV Testing- Screening Intervals- HPV Vaccine Updates-
Your PAP and HPV Update 2015 Connie Mao, MD University of Washington Goals Primary HPV Testing- Is it time to stop doing pap smears? Screening Intervals- Should patients have a choice? HPV Vaccine Updates-
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationScreening for Cervical Cancer. Grand Rounds 1/16/13 Meggan Linck
Screening for Cervical Cancer Grand Rounds 1/16/13 Meggan Linck Cervical Cancer Worldwide 2 nd most common and 5 th deadliest U.S. 8 th most common 80% occur in developing world Median age at diagnosis
More informationChapter 5. M.G. Dijkstra L. Rozendaal M. van Zummeren F.J. van Kemenade P.J.F. Snijders C.J.L.M. Meijer J. Berkhof. Submitted for publication
Chapter 5 CIN3 and cancer risks after primary HPV DNA testing and cytology triage in cervical cancer screening: fifteen years follow-up of a randomized controlled trial M.G. Dijkstra L. Rozendaal M. van
More informationP16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.
P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future. Mark H Stoler, MD University of Virginia Health System, Charlottesville, VA,
More informationPrior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory
Prior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory Baowen Zheng, MD 1 ; Zaibo Li, MD, PhD 2 ; Christopher C. Griffith, MD, PhD
More informationCervical Cancer Screening
Todd R. Jenkins, MD, MSHA Senior Vice Chair Director, Division of Women s Reproductive Healthcare Learning Objectives Describe the etiology, natural history, and usage of the human papillomavirus (HPV)
More informationEmerging Challenges in Primary Care. Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing
Emerging Challenges in Primary Care Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause Practitioner
More informationMolecular Triage: Partial and Extended Genotyping and More!
Molecular Triage: Partial and Extended Genotyping and More! Thomas C. Wright, Jr. MD Professor Emeritus Columbia University, New York Pathologist, Enzo Clinical Laboratories, Farmingdale, NY Disclosures
More informationHPV Primary Screening Update. Prof. Vu Ba Quyet Director of NO&G hospital
HPV Primary Screening Update Prof. Vu Ba Quyet Director of NO&G hospital 1 Who can we not worry about? 2 Key questions Who should be screened? Starting age? Ending age? How often? How to manage results?
More informationNatural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma
14,670 5796 United States/ Canada 17,165 8124 Central America 48,328 21,402 South America 59,929 29,814 Europe 78,896 61,670 Africa 157,759 86,708 Southcentral Asia 61,132 31,314 Eastern Asia 42,538 22,594
More informationHPV Molecular Diagnostics and Cervical Cytology. Philip E. Castle, PhD, MPH American Society for Clinical Pathology (ASCP) March 15, 2012
HPV Molecular Diagnostics and Cervical Cytology Philip E. Castle, PhD, MPH American Society for Clinical Pathology (ASCP) March 15, 2012 Disclosures & Disclaimers I serve on a Merck Data and Safety Monitoring
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationOctober 9, Dear Ms. Chowdhury:
October 9, 2017 Joya Chowdhury, MPH Senior Coordinator, USPSTF Department of Health and Human Services Agency for Healthcare Research and Quality Center for Evidence and Practice Improvement Room 06E65A
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationCervical-Cancer Screening with Human Papillomavirus and Cytologic Cotesting
The new england journal of medicine clinical practice Caren G. Solomon, M.D., M.P.H., Editor Cervical-Cancer Screening with Human Papillomavirus and Cytologic Cotesting Mark Schiffman, M.D., M.P.H., and
More informationLessons From Cases of Screened Women Who Developed Cervical Carcinoma
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationUpdate on HPV Testing. Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories
Update on HPV Testing Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories Disclosures In accordance with ACCME guidelines, any individual
More informationHPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe. Mark H. Stoler, MD ASC Companion Meeting USCAP 2008
OBJECTIVES: HPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe Mark H. Stoler, MD ASC Companion Meeting USCAP 2008 1. Describe the concept of marker validation in the context of HPV tests. 2. Present
More informationUtilization of the Biomarkers to Improve Cervical Cancer Screening
Utilization of the Biomarkers to Improve Cervical Cancer Screening Elena BERNAD Victor Babes University of Medicine and Pharmacy Timisoara, Romania Cervical cancer is at the second most common cancer in
More information32 OBG Management May 2015 Vol. 27 No. 5 obgmanagement.com
The Advisory Committee on Immunization Practices recommends routine vaccination against HPV in 11- and 12-year-olds, although the age can range from 9 to 26 years (for those who have not been vaccinated
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More information9/19/17. Emerging Challenges in Primary Care: Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing. Faculty.
Emerging Challenges in Primary Care: 2017 Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause
More informationNo Disclosures. Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results. Objectives 5/9/2016
Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical Director, PPWI Medical College of Wisconsin May 6,
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More informationCancer Treatment Centers of America: Supercharge Your Knowledge: A Focus on Breast, Cervical and Prostate Screening Guidelines and Controversies
8 ACOFP 55th Annual Convention & Scientific Seminars Cancer Treatment Centers of America: Supercharge Your Knowledge: A Focus on Breast, Cervical and Prostate Screening Guidelines and Controversies Anthony
More informationDisclosures. Goal of Cervical Cancer Screening. Update on Cervical Cancer Screening: Appropriate Use of Pap and HPV Testing
Disclosures Update on Cervical Cancer Screening: Appropriate Use of Pap and HPV Testing Consultant and Speaker: Hologic Nancy R. Berman MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner/Colposcopist Certified
More informationCervical cancer screening in vaccinated population
Cervical cancer screening in vaccinated population Cytology and molecular testing Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol Oncol Izmir, November
More informationProposed National Coverage Determination for Screening for Cervical Cancer with Human Papillomavirus (HPV) Testin
Proposed Decision Memo for Screening for Cervical Cancer with Human Papillomavirus (HPV) Testing (CAG-00442N) Decision Summary The Centers for Medicare & Medicaid Services (CMS) proposes that the evidence
More information(Pap) results, ie, abnormal squamous cells of undetermined significance (ASCUS). According to
The Role of Human Papillomavirus Type 16/18 Genotyping in Predicting High-Grade Cervical/Vaginal Intraepithelial Neoplasm in Women With Mildly Abnormal Papanicolaou Results Ming Guo, MD 1 ; Yun Gong, MD
More informationRisk : How does it define cervical cancer screening?
Risk : How does it define cervical cancer screening? Alan G. Waxman, MD, MPH Dept. of Obstetrics and Gynecology University of New Mexico The University of New Mexico Disclosures I have no commercial interests
More informationScreening for Cervical Cancer Reference List
SEER Cancer Statistics Factsheets: Cervix Uteri Cancer. [cited May 12, 2016]; Available from: http://seer.cancer.gov/statfacts/html/cervix.html Healthy People 2020. [cited May 12, 2016]; Available from:
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationThese comments are an attempt to summarise the discussions at the manuscript meeting. They are not an exact transcript.
Dear dr. Weber, We would like to thank you for the review of our manuscript entitled Cervical screening with an interval beyond five years requires different rescreen times for HPV-negative and HPVpositive,
More informationPap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed???
Pap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed??? Arlene Evans-DeBeverly, PA-C Copyright 2012 There are always ongoing changes in gynecology, including the
More informationCME/SAM. High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up
Anatomic Pathology / HPV Testing in Negative Papanicolaou Tests High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up Michael
More informationThe ATHENA HPV study underrepresents other high-risk HPV genotypes when compared with a diverse New York City population
Accepted: 6 March 2017 DOI: 10.1111/cyt.12440 ORIGINAL ARTICLE The ATHENA HPV study underrepresents other high-risk HPV genotypes when compared with a diverse New York City population G. Ramos Rivera a
More informationSince the 1960s, colposcopy of the cervix with
Original Research Relevance of Random Biopsy at the Transformation Zone When Colposcopy Is Negative Warner K. Huh, MD, Mario Sideri, MD, Mark Stoler, MD, Guili Zhang, PhD, Robert Feldman, MD, and Catherine
More informationCervical Cancer 4/27/2016
Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about
More informationSafe, Confident, QIAsure
Safe, Confident, QIAsure A new cervical cancer screening test Sample to Insight QIAsure: A breakthrough solution in Women s Health We are at a turning point in the battle against cervical cancer. The global
More informationOriginal Articles. Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests?
Original Articles Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests? Siavash Azadmanesh Samimi, MD; Roxanne R. Mody, MD;
More informationSupplements to the European Guidelines on Prevention of Cervical Cancer
Asturias, 23 October, 2011 Asturias, 23 October Supplements to the European Guidelines on Prevention of Cervical Cancer M. Arbyn Unit Cancer Epidemiology, IPH, Brussels, Belgium Rue Juliette Wytsmanstraat
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationDisclosures & images
Cervical Cancer Screening: New Approaches Levi S. Downs, Jr., MD Disclosures & images During the previous 12 months, I have been a consultant for and received honoraria from Merck. Images are attributed
More informationJean-Christophe Noël and Philippe Simon. 1. Introduction
Analytical Cellular Pathology Volume 2015, Article ID 746502, 4 pages http://dx.doi.org/10.1155/2015/746502 Research Article Limitations on the Detection Rate of High-Risk HPV by Hybrid Capture 2 Methodology
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationData spark new directions in cervical cancer
reprinted from june 2014 pathology laboratory medicine laboratory management Joe Mahoney Data spark new directions in cervical cancer William Check, PhD When Mark Stoler, MD, stood up to speak at the 30th
More informationXinxin Du, Shufang Jiang, Aijun Liu, Yurong Fu, Yun Zhang, Yuanguang Meng *
Biomedical Research 2018; 29 (1): 203-208 ISSN 0970-938X www.biomedres.info Comparison of HPV testing by real-time fluorescent PCR and hc2 for detection of high-grade cervical intraepithelial neoplasia
More informationEvaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology- Negative Results
Anatomic Pathology / HPV DNA Testing in Women With Negative Cytology Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology- Negative Results Thomas C. Wright Jr,
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationClinical Relevance of HPV Genotyping. A New Dimension In Human Papillomavirus Testing. w w w. a u t o g e n o m i c s. c o m
Clinical Relevance of HPV Genotyping A New Dimension In Human Papillomavirus Testing Human Papillomavirus: Incidence HPV prevalence was 26.8% for women in US aged 14 59 yrs 1 20 million Americans are currently
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationPrimary High Risk HPV Testing with Cytology Triage
Primary High Risk HPV Testing with Cytology Triage NHS Cervical Screening Programme Public Health England leads the NHS Screening Programmes Human papillomavirus (HPV) High risk (HR) HPV is associated
More informationCervical Cancer Prevention in the 21 st Century Changing Paradigms
Cervical Cancer Prevention in the 21 st Century Changing Paradigms Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M.
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationONCOLOGY LETTERS 8: , 2014
1528 Uneven distribution of human papillomavirus 16 in cervical carcinoma in situ and squamous cell carcinoma in older females: A retrospective database study SONIA ANDERSSON 1, MIRIAM MINTS 1, ULF GYLLENSTEN
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationAn Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program
An Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program Susan Baum, MD, MPH NM Nurse Practitioner Council Annual Conference April 20, 2012 I have no commercial relationships related
More information1/12/2016. I do not engage in any lucrative deals that require disclosure.
I do not engage in any lucrative deals that require disclosure. Sabrina Hofmeister, DO Assistant Professor Columbia St. Mary s Family Medicine Residency Program MCW Department of Family and Community Medicine
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6857 Cost-Effectiveness of Strategies for Detection CIN2+ in Women with ASC-US Pap Smears in Thailand RESEARCH ARTICLE Cost-Effectiveness Analysis of Different
More informationTHE NEW ERA OF PRIMARY HPV SCREENING FOR PREVENTION OF INVASIVE CERVICAL CANCER
THE NEW ERA OF PRIMARY HPV SCREENING FOR PREVENTION OF INVASIVE CERVICAL CANCER Philip E Castle 1,2 1. Cancer Modelling Group, Lowy Cancer Research Centre, University of New South Wales, Australia. 2.
More informationUpdate on Cervical Cancer Screening. Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014
Update on Cervical Cancer Screening Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014 Objectives Review the natural history of HPV as it relates to cervical cancer screening
More informationUpdate on Cervical Cancer Screening
Update on Cervical Cancer Screening Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014 Objectives Review the natural history of HPV as it relates to cervical cancer screening
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationHe Said, She Said: HPV and the FDA. Audrey P Garrett, MD, MPH June 6, 2014
He Said, She Said: HPV and the FDA Audrey P Garrett, MD, MPH June 6, 2014 Disclosure Speaker for Merck Gardasil Speaker for Hologic Thin Prep and Cervista Cervical Cancer Screening: 21 st century Dr. Papanicolaou
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationCervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients
Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients Richard Hopley, MD, Alexandra Gillespie, MD* Laboratory Medicine 47:1:52-56 CLINICAL HISTORY Patients:
More informationMolecular Analysis in the Diagnosis and Management of Lesions of Uterine Cervix: The 95% solution. Mark H. Stoler, MD PSC Symposium USCAP 2008
Molecular Analysis in the Diagnosis and Management of Lesions of Uterine Cervix: The 95% solution Mark H. Stoler, MD PSC Symposium USCAP 2008 Objectives: This presentation will briefly review the currently
More informationAbnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing
280 Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing Giovanni Negri, MD Bettina Rigo, BS Fabio Vittadello, ScD Christine Mian, ScD Eduard Egarter-Vigl, MD Department of Pathology,
More informationDysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.
CLINICAL PRACTICE GUIDELINE Guideline Number: DHMP_DHMC_PG1015 Guideline Subject: Routine Cervical Cancer Screening Effective Date: 9/2018 Revision Date: 9/2019 Pages: 2 of 2 Quality Management Committee
More informationNorthern Ireland cervical screening programme. Information for primary care and smear takers
Northern Ireland cervical screening programme Information for primary care and smear takers From January 2011, the Northern Ireland cervical screening programme will no longer invite women aged under 25
More informationQuality Improvement Measures for Cervical Cytology Screening
Quality Improvement Measures for Cervical Cytology Screening Dr. Julie Baker-Townsend, DNP, FNP-BC, WHNP-BC Assistant Professor University of North Florida School of Nursing Jacksonville, Florida, U.S.A
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationAbsolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women
Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women 2145 Philip E. Castle, Ph.D., M.P.H. 1 Sholom Wacholder, Ph.D. 1 Mark E. Sherman,
More informationEmerging Laboratory Diagnostic Options for Sexually-transmitted Infections
Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections Erik Munson Wheaton Franciscan Laboratory Marquette University Milwaukee, Wisconsin 1 OBJECTIVES I. Appreciate the changing epidemiology
More informationCervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix
DOI:10.31557/APJCP.2019.20.2.377 Cervical Screening Results Leading to Detecting Cervical AIS RESEARCH ARTICLE Editorial Process: Submission:09/27/2018 Acceptance:01/18/2019 Cervical Screening Results
More informationAn Update on HPV and Cervical Cancer Prevention
An Update on HPV and Cervical Cancer Prevention Nancy R. Berman MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner/Colposcopist Certified Menopause Practitioner (NAMS) Millennium Affiliated Physicians Division
More informationIn this Update, I report on the latest US
UPDATE Gynecologic cancer Jason D. Wright, MD Dr. Wright is Sol Goldman Associate Professor, Chief of Division of Gynecologic Oncology, Vice Chair of Academic Affairs, Department of Obstetrics and Gynecology,
More informationWelcome. THE ROLE OF oncofish cervical ASSESSMENT OF CERVICAL DYSPLASIA. March 26, 2013
THE ROLE OF oncofish cervical IN THE ASSESSMENT OF CERVICAL DYSPLASIA The phone lines will open, 15 minutes prior to the start of the webinar. Toll Free: 1-800-867-0864. Entry Code: 83956484. You may download
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationCervical cancer screening programs that use conventional cytology. Review
Annals of Internal Medicine Review Liquid-Based Cytology and Human Papillomavirus Testing to Screen for Cervical Cancer: A Systematic Review for the U.S. Preventive Services Task Force Evelyn P. Whitlock,
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationUpdated ASCCP Consensus Guidelines For Managing Diagnosed Cervical Cancer Precursors Michael A. Gold, M.D.
Updated ASCCP Consensus Guidelines For Managing Diagnosed Cervical Cancer Precursors Michael A. Gold, M.D. 27 May, 2014 London, England Faculty Disclosure X No, nothing to disclose Yes, please specify
More informationChapter 14: Role of Triage Testing in Cervical Cancer Screening
Chapter 14: Role of Triage Testing in Cervical Cancer Screening Diane Solomon The classic model of cervical cancer prevention primary screening with cytology, followed by diagnostic colposcopically directed
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 13: , 2017
3032 Clinical progress of human papillomavirus genotypes and their persistent infection in subjects with atypical squamous cells of undetermined significance cytology: Statistical and latent Dirichlet
More informationSamuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida
Making sense of the new Pap smear screening guidelines. Samuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida Case 17 year old G1P0010 with first sexual encounter
More informationRESEARCH. open access
open access Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised
More informationHuman Papilloma Virus (HPV) Sequencing Using a Cytobrush (code 41416) Notice of Assessment
Human Papilloma Virus (HPV) Sequencing Using a Cytobrush (code 41416) Notice of Assessment June 2013 DISCLAIMER: This document was originally drafted in French by the Institut national d'excellence en
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More information